T. J. Walsh, G. P. Melcher, M. G. Rinaldi, J. Lecciones, D. A. McGough, P. Kelly, J. Lee, D. Callender, M. Rubin and P. A. Pizzo, “Trichosporon beigeli, an Emerging Pathogen Resistant to Amphotericin B,” Journal of Clinical Microbiology, Vol. 28, No. 7, 1990, pp. 1616-1622.

has been cited by the following article:

• TITLE: Utility of Miconazole Therapy for Trichosporon Fungemia in Patients with Acute Leukemia

  AUTHORS: Kazunori Nakase, Kei Suzuki, Taiichi Kyo, Yumiko Sugawara, Shinichi Kageyama, Naoyuki Katayama

  KEYWORDS: Miconazole; Trichosporon; Fungemia; Acute Leukemia

  JOURNAL NAME: Advances in Microbiology, Vol.3 No.8A, December 26, 2013

  ABSTRACT: Invasive trichosporonosis is an extremely rare mycosis, but Trichosporon fungemia (TF) in patients with hematologic malignancies has been increasingly recognized to be a fulminant and highly lethal infection. Although the utility of azole therapy has been demonstrated in several observations, little is known about the efficacy of one of azoles, miconazole (MCZ). To assess its therapeutic role, we retrospectively investigated 6 cases of TF in patients with acute leukemia receiving MCZ containing regimens. Successful outcome was obtained in 4 patients [MCZ + amphotericin B (AmB) in 2, MCZ only and MCZ + fluconazole (FLCZ) + AmB in one each], but not in 2 (MCZ + FLCZ + AmB and MCZ + FLCZ in one each). Although MCZ and AmB exhibited good in vitro activities against isolates from all patients, FLCZ had such finding from only one patient. Considering the reportedly limited utility of AmB, MCZ seemed to play a critical role even in the combination therapies for TF. Despite the release of newer azoles and other classes of antifungals, the use of MCZ remains a potential therapeutic approach for TF in patients with acute leukemia.